维普中文期刊产品整合服务
4篇 您的检索式:作者名="Joan Colomer"
    题名 作者 年代 出处 被引量
1Usefulness of the PERFORM questionnaire to measure fatigue in cancer patients with anemia: a prospective, observational study显示文摘Pere Gascón César A. Rodríguez Vicente Valentín Jesús García Mata Joan Carulla Javier Cassinello Ramón Colomer Eva Baró 2013Supportive Care in Cancer2013,,:1
2Process diagnosis based on qualitative trend similarities using a sequence matching algorithm显示文摘Fco I Gamero Joaquim Mel6ndez Joan Colomer 2014Journal of Process Control2014,24,9:1
3Lesns in urban monitoring taken from sustainable and livable cities to better address the Smart Cities initiative 显示文摘Marsal - Llacuna Maria - Lluisa Colomer - Llinas Joan Melendez - Frigola Joaquim 2015Technological Forecasting and Social Change2015,90,:1
4Monitoring hepatitis C virus treatment rates in an Opioid Treatment Program:A longitudinal study显示文摘BACKGROUND Direct-acting antivirals(DAAs)are recommended for the treatment of hepatitis C virus(HCV)infection in patients treated with methadone or buprenorphine.AIM To assess HCV treatment rates in an Opioid Treatment Program(OTP).METHODS This longitudinal study included 501 patients(81.4%men,median age:45 years;interquartile range:39-50 years)enrolled in an OTP between October 2015 and September 2017.Patients were followed until September 2019.Data on sociodemographics,substance use,HCV infection,human immunodeficiency virus(HIV)infection and laboratory parameters were collected at entry.We analyzed medical records to evaluate HCV treatment.Kaplan-Meier methods and Cox regression models were used to analyze the DAA treatment uptake and to identify treatment predictors.RESULTS Prevalence of HCV and HIV infection was 70%and 34%,respectively.Among anti-HCV-positive(n=336)patients,47.2%,41.3%,and 31.9%used alcohol,cannabis,and cocaine,respectively.HCV-RNA tests were positive in 233(69.3%)patients.Twentyeight patients(8.3%)cleared the infection,and 59/308(19.1%)had received interferon-based treatment regimens before 2015.Among 249 patients eligible,111(44.6%)received DAAs.Treatment rates significantly increased over time from 7.8/100 person-years(p-y)(95%CI:5.0-12.3)in 2015 to 18.9/100 p-y(95%CI:11.7-30.3)in 2019.In a multivariate analysis,patients with HIV co-infection were twice as likely to receive DAAs(HR=1.94,95%CI:1.21-3.12)than patients with HCV mono-infection.Current drug use was an independent risk factor for not receiving treatment against infection(HR=0.48,95%CI:0.29-0.80).CONCLUSION HCV treatment is evolving in patients with HCV-HIV co-infection.Ongoing drug use while in an OTP might negatively impact the readiness to treat infection.Arantza Sanvisens Inmaculada Rivas Eva Faure Néstor Espinach Anna Hernandez-Rubio Xavier Majó Joan Colom Robert Muga 2020World Journal of Gastroenterology2020,26,38:0
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费